November 1, 2024 10:38 AM EDTUpdated 02:15 PM
News Briefing

FDA re­moves hold on three CARs­gen CAR-T tri­als; Ono pass­es on itolizum­ab

ENDPOINTS

Plus, news about Kymera Ther­a­peu­tics, Nanoscope, Eu­prax­ia, Al­pha Cog­ni­tion and Eye­Point:

FDA’s de­ci­sion on CARs­gen’s CAR-T ther­a­pies: The FDA on Thurs­day

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times